CMHC 2014 Symposium: Achieving Glycemic Control: A Focus on Incretin-Based Therapy and SGLT2 Inhibitors

Newer treatment options, including SGLT2 inhibitors, DPP-4 inhibitors and GLP-1 receptor agonists, and several fixed-dose combinations are available or are in development, and may change the treatment paradigm for T2DM. Learn how these therapies have the potential to work synergistically in combination with other available interventions to achieve glycemic control and to reduce overall cardiometabolic risk for individuals with T2DM.

Supported by an educational grant from AstraZeneca

Introductory Remarks

Chairperson: George L. Bakris, MD

The Role of Incretin Therapies and Effects on Metabolic Homeostasis

Faculty: Richard E. Pratley, MD

Renal Involvement in the Control of Plasma Glucose

Faculty: Mark E. Molitch, MD

Current and Novel Approaches to Glycemia Management: A Focus on Combination Therapy

Faculty: Sunder Mudaliar, MD

Exploring Synergistic Approaches to Improve Glucose Control and CV Risk Factors: Interactive, Case-Based Scenarios, Panel Discussion and Debate along with Audience Q&A

Moderator: George L. Bakris, MD

Presenters: Mark E. Molitch, MDSunder Mudaliar, MDRichard E. Pratley, MD